SG Americas Securities’s Immunome IMNM Stock Holding History

SG Americas Securities’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$272K	Sell	12,817 -23,153	-64%	-$495K	﹤0.01%	2642
2026 Q1	$787K	Sell	35,970 -126,198	-78%	-$2.81M	﹤0.01%	1921
2025 Q4	$3.48M	Buy	162,168 +153,399	+1,749%	+$2.69M	﹤0.01%	1250
2025 Q3	$103K	Buy	+8,769	New	+$87.2K	﹤0.01%	3070
2025 Q2	–	Sell	-26,599	Closed	-$179K	–	3249
2025 Q1	$179K	Buy	+26,599	New	+$255K	﹤0.01%	2613
2024 Q4	–	Sell	-72,627	Closed	-$1.06M	–	3351
2024 Q3	$1.06M	Sell	72,627 -17,877	-20%	-$254K	﹤0.01%	1043
2024 Q2	$1.09M	Buy	+90,504	New	+$1.42M	0.01%	1268

Other funds holding IMNM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

SG Americas Securities's IMNM Position: Q2 2026 in Review

SG Americas Securities reduced its Immunome (IMNM) stake by 64% in Q2 2026, selling an estimated $495K and leaving 12,817 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #2642.

SG Americas Securities first reported a position in IMNM in Q2 2024 and has held it in 7 quarters since. The position peaked at $3.48M in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

SG Americas Securities held 12,817 shares of Immunome worth $272K as of Q2 2026.
SG Americas Securities sold 23,153 Immunome shares in Q2 2026, an estimated $495K.
Immunome made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2642 holding.
SG Americas Securities first reported a position in Immunome in Q2 2024 and has held it in 7 quarters since.
SG Americas Securities's Immunome position peaked at $3.48M in Q4 2025.
202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.